MetMAb/erlotinib improved PFS, OS in patients with NSCLC

Harris, Jason; Southall, Jennifer
October 2010
Hem/Onc Today;10/25/2010, Vol. 11 Issue 20, p18
The article discusses research being done on the effectiveness of MetMab and erlotinib in patients with non-small-cell lung cancer (NSCLC), which references a study by David Robert Spigel and colleagues presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy from October 8-12, 2010.


Related Articles

  • Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer. Yang, C.H.; Tsai, C.M. // British Journal of Cancer;1/21/2002, Vol. 86 Issue 2, p190 

    The role of new cytotoxic agents like gemcitabine has not yet been proven in the neoadjuvant settings. We designed a phase II study to test the feasibility of using gemcitabine and cisplatin before local treatment for stage III non-small cell lung cancer patients. Patients received three cycles...

  • Targeting the Lung: Preclinical and Comparative Evaluation of Anticancer Aerosols in Dogs with Naturally Occurring Cancers. Chand Khanna; David M. Vail // Current Cancer Drug Targets;Aug2003, Vol. 3 Issue 4, p265 

    Pet dogs with naturally occurring cancers offer a novel opportunity for the study of both cancer biology and therapy. The following review will provide the rationale for the use of these spontaneous cancer models in translational research, particularly in the development of anticancer aerosols....

  • First-line gefitinib superior to carboplatin-paclitaxel in nonsmokers with advanced pulmonary adenocarcinoma.  // Hem/Onc Today;9/25/2009, Vol. 10 Issue 18, p35 

    The article discusses research which revealed that first-line gefitinib is superior over carboplatin-paclitaxel as initial treatment for East Asian patients with advanced pulmonary adenocarcinoma who were non-smokers.

  • SATURN: Erlotinib showed benefit regardless of biomarker status.  // Hem/Onc Today;9/25/2009, Vol. 10 Issue 18, p41 

    The article reports that the Sequential Tarceva in Unresectable Non-Small Cell Lung Cancer (SATURN) trial has demonstrated the effectiveness and safety of erlotinib therapy for patients with non-progressive non-small cell lung cancer.

  • Gefitinib produced higher response rate, better PFS in advanced lung cancer. Adams, Stacey L.; Haigh, Christen; Harris, Jason // Hem/Onc Today;9/25/2009, Vol. 10 Issue 18, p42 

    The article discusses research which revealed that gefitinib did not improve the overall survival (OS) for patients with advanced lung cancer but has produced higher response rates and progression-free survival (PFS).

  • Lung cancer • 4: Chemotherapy for non-small cell lung cancer: the end of the beginning. Cullen, M. // Thorax;Apr2003, Vol. 58 Issue 4, p352 

    Charts the development of chemotherapy in non-small cell lung cancer (NSCLC) and discusses its role in advanced disease, as a neoadjuvant therapy before definitive surgery, as an adjuvant after surgery, in subgroups of patients defined by age and performance status, and in patients who relapse...

  • Erlotinib marginally cost effective for NSCLC.  // PharmacoEconomics & Outcomes News;4/17/2010, Issue 601, p7 

    The article discusses research on the cost effectiveness of erlotinib for advanced non-small cell lung cancer (NSCLC), by P. A. Bradbury and colleagues, published in the February 2010 issue of the "Journal of the National Cancer Institute."

  • Wondering What You Missed in BioWorld Insight?  // BioWorld Today;5/30/2012, p7 

    The article presents an overview of the reports in "BioWorld Insight" journal, including a report which explored the technologies that are making undruggable targets accessible to therapeutic intervention and the withdrawal of lung cancer drug Iressa (gefitinib) in the U.S.

  • Vinflunine noninferior to docetaxel for refractory NSCLC.  // Hem/Onc Today;4/25/2010, Vol. 11 Issue 8, p22 

    The article examines a phase-3 trial, which showed that vinflunine is noninferior to docetaxel in treating patients with non-small cell lung cancer whose platinum-based first-line chemotherapy failed.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics